What is CytomX Therapeutics Inc (CTMX)?
CytomX Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel immuno-oncology therapies. The company focuses on creating conditionally activated biologics that aim to enhance the immune system’s ability to target cancer cells while minimizing side effects. CytomX utilizes its proprietary Probody technology platform to engineer antibodies that remain inactive until they reach the tumor microenvironment. This approach is designed to improve the safety and efficacy of cancer treatments. The company’s pipeline includes candidates targeting various tumor types and immune checkpoints. CytomX collaborates with pharmaceutical partners to advance its therapeutic programs. Its work is situated within the broader field of cancer immunotherapy, seeking to develop innovative treatments that harness the immune system against malignancies.
CytomX Therapeutics Inc Stock Price Today: Live Overview
The price today is shaped by trading dynamics, as CytomX Therapeutics Inc stands at $4.47. Today’s price range extends from $4.38 to $4.74, with a daily percentage movement of 0%.
FAQ: CytomX Therapeutics Inc (CTMX)
What is the current price of CTMX stock?
The current trading price is $4.47.
Does CTMX pay dividends?
CytomX Therapeutics Inc does not pay dividends.
Does CTMX have a formal corporate presence or regional headquarters in the UAE?
CytomX Therapeutics Inc operates in the UAE via partners and does not have an official regional office or subsidiary.
What is CTMX best known for?
CytomX Therapeutics Inc is most famous for its development of Probody therapeutics for cancer treatment.
What assets are typically shown together with CTMX?
Commonly shown alongside CTMX: Axsome Therapeutics Inc, CNS Pharmaceuticals, Inc., CNS Pharmaceuticals, Inc.
Latest shares articles



